625835-52-1

Basic information

• Product Name: 3-[3-(dimethylamino)propyl]-4-phenyl-4-(trichloromethyl)-3,4-dihydroquinazolin-2(1H)-one
• Synonyms: 3-[3-(dimethylamino)propyl]-4-phenyl-4-(trichloromethyl)-3,4-dihydroquinazolin-2(1H)-one
• CAS NO: 625835-52-1
• Molecular Weight: 426.773
• Mol File: 625835-52-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-[3-(dimethylamino)propyl]-4-phenyl-4-(trichloromethyl)-3,4-dihydroquinazolin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[3-(dimethylamino)propyl]-4-phenyl-4-(trichloromethyl)-3,4-dihydroquinazolin-2(1H)-one(625835-52-1)
• EPA Substance Registry System: 3-[3-(dimethylamino)propyl]-4-phenyl-4-(trichloromethyl)-3,4-dihydroquinazolin-2(1H)-one(625835-52-1)

Safety Data

• Hazardous Substances Data: 625835-52-1(Hazardous Substances Data)

Upstream product

• 35382-88-8 N-(2-benzoylphenyl)-2,2,2-trichloroacetamide 
• 109-55-7 1-amino-3-(dimethylamino)propane 
• 2835-77-0 (2-aminophenyl)(phenyl)methanone 

Downstream Products

• 625835-61-2 3-(3-dimethylamino-propyl)-4-phenyl-3,4-dihydro-1H-quinazolin-2-one 

Relevant articles and documents

A novel class of sodium/calcium exchanger inhibitor: Design, synthesis, and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives

Design, synthesis, and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives as inhibitors of the sodium/calcium (Na+/Ca2+) exchanger are discussed. These studies, based on a lead compound 9a, which was identified in our library, involved systematic modification of three regions and revealed that (1) the 3,4-dihydro-2(1H)- quinazolinone having a tertiary amino alkyl side chain at the 3-position is essential for activity, (2) a nonsubstituted phenyl ring is most suitable for high activity, and (3) introduction of a 4-substituted piperidine moiety enhanced the activity, in particular 4-benzylpiperidin-1-yl showed strong inhibitory activity. Based on these SAR studies, a structurally novel and highly potent inhibitor against the Na+/Ca2+ exchanger, 12g (SM-15811), was discovered. In particular, SM-15811 directly inhibited the Na+-dependent Ca2+ influx via the Na+/Ca 2+ exchanger in cardiomyocytes with a high potency. The activity was almost two orders more potent than the lead compound 9a and SM-15811 exerted a protective effect against myocardial ischemic reperfusion injury. These Na +/Ca2+ inhibitors could have a therapeutic potential for the treatment of ischemic reperfusion injury.